Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy
British Journal of Pharmacology · 2026-08 · 183 (16) · 4562-4575
DOI: 10.1111/bph.70472 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 30.04.2026. Verfasst von Wen-Hui Liu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China. Hauptthemen laut MEDLINE: Bifidobacterium, Lactose, Immunotherapy, Neoplasms. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Chinese Pharmaceutical Association Hospital Pharmacy Department, National Natural Science Foundation of China, Scientific Foundation of Hunan.
Abstract (Originalsprache)
Background and Purpose The potential predictive and therapeutic value of Bifidobacterium in immune checkpoint inhibitor (ICI) treatment has been widely studied. However, the value of its genetic determinants on the prognosis of ICI treatment remains unclear. Experimental Approach We examined the associations between 11 single nucleotide polymorphisms (SNPs) located at host genes associated with Bifidobacterium abundance and the outcomes of ICI treatment in 370 eligible Chinese cancer patients. Key Results LCT/MCM6 SNPs, rs3739020, rs3739022, rs56263017 and rs55809728, were strongly associated with overall survival (OS), and the LCT haplotype analysis showed that genetically predicted lactose poor metabolisers exhibited significantly poorer OS ( P ‐value = 0.002, adjusted HR = 0.45, 95%CI = 0.27–0.74). In polygenic SNP analysis, the genetically inferred high galactose level carriers exhibited significantly prolonged OS ( P ‐value = 0.007, adjusted HR = 0.32, 95%CI = 0.14–0.73) and progression‐free survival (PFS, P ‐value = 0.001, adjusted HR = 0.45, 95%CI = 0.29–0.71). All four SNPs and the lactose metabolic phenotype were not associated with the occurrence of overall immune‐related adverse events (irAEs). Two‐sample mendelian randomisation analysis showed genetically predicted Bifidobacterium abundance correlated with lactose metabolism pathway abundance ( P value = 0.012, Beta coefficient = 0.549). Conclusions and Implications Lactose metabolism pathway SNPs, which are linked to Bifidobacterium abundance in prior studies, have prognostic value for immunotherapy efficacy in Chinese cancer patients, and the genetically predicted lactose extensive and intermediate metabolisers exhibited better immunotherapy efficacy. These findings remain exploratory and require further validation with direct microbiome and metabolite measurements.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, the Second Xiangya Hospital, Central South University, Changsha, China.
- Institute of Clinical Pharmacy, Central South University, Changsha, China.
- Hunan Pharmaceutical Development Investment Group Co., Ltd., Changsha, China.
- Department of Pharmacy, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, Changsha, China.
- Hunan Provincial Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University, Changsha, China.
Förderung
- Chinese Pharmaceutical Association Hospital Pharmacy Department
- National Natural Science Foundation of China
- Scientific Foundation of Hunan
- Degree & Postgraduate Education Reform Project of Central South University
Zitieren
APA
Liu, W. H., Xiao, C. L., Luo, Z. Y., Zhu, Y. J., Li, W. R., Ren, H., Guo, Z., & Luo, J. Q. (2026). Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy. British Journal of Pharmacology, 183(16), 4562-4575. https://doi.org/10.1111/bph.70472
Vancouver
Liu WH, Xiao CL, Luo ZY, Zhu YJ, Li WR, Ren H, et al. Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy. British Journal of Pharmacology. 2026;183(16):4562-4575. doi:10.1111/bph.70472
BibTeX
@article{Liu2026,
author = {Liu, Wen-Hui and Xiao, Chen-Lin and Luo, Zhi-Ying and Zhu, Ya-Jun and Li, Wen-Ru and Ren, Huan and Guo, Zhen and Luo, Jian-Quan},
title = {Host genetic variants in the lactose metabolism pathway associated with bifidobacterium abundance have prognostic value for immunotherapy efficacy},
journal = {British Journal of Pharmacology},
year = {2026},
volume = {183},
number = {16},
pages = {4562--4575},
doi = {10.1111/bph.70472}
}
EUVIMED